EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug …

WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company’s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET.

Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; and Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Houston, Deputy Chair For Ophthalmology, Blanton Eye Institute.

To access the event, please dial (877) 870-4263 from the

Read More